Abstract
BackgroundWidely used human growth hormone assay is based on the method using the isotope which needs special facilities. In this study, we compared the newly developed Access Ultrasensitive hGH assay (Beckman Coulter, Inc.) which is a chemiluminescence enzyme immunoassay (CLEIA), and GH kit “Daiichi” (Daiichi Radioisotope LABS, LTD) which is a monoclonal antibody-based immunoradiometric assay (IRMA). MethodsForty-three serum samples from 9 patients with normal pituitary function were used to investigate the correlation between the two assays described above. Sera of 45 patients with various endocrine disorders were measured in two measurement methods. ResultsAnalytical sensitivity of the CLEIA was calculated as 0.002 ng/mL and the precision was satisfied. The Access Ultrasensitive hGH and the IRMA showed a good correlation, however, the slope was about half. In analysis of 45 patients, only one patient with residual pituitary adenoma showed slightly low value compared with other patients. ConclusionThe Access Ultrasensitive hGH is a fully automated sensitive immunoassay system with good precision and fast measuring time, and correlates highly with the IRMA. The Access Ultrasensitive hGH assay, with no need for radioactive materials, is therefore suitable for routine use in the clinical laboratory.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
